Michael Rice - 10 Jan 2022 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role: CEO, Director
Signature: /s/ Michael Rice
Issuer symbol: BLFS
Transactions as of: 10 Jan 2022
Net transactions value: -$983,127
Form type: 4
Filing time: 12 Jan 2022, 19:00:20 UTC
Previous filing: 30 Dec 2021
Next filing: 03 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BLFS	Common Stock	Options Exercise	$29,665	+16,666	+6.4%	$1.78^*	276,121	10 Jan 2022	Direct
transaction	BLFS	Common Stock	Sale	$513,813	-16,666	-6%	$30.83	259,455	10 Jan 2022	Direct	F1, F2
transaction	BLFS	Common Stock	Options Exercise	$29,665	+16,666	+6.4%	$1.78^*	276,121	12 Jan 2022	Direct
transaction	BLFS	Common Stock	Sale	$528,646	-16,666	-6%	$31.72	259,455	12 Jan 2022	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BLFS	Employee Stock Option	Options Exercise	$0	-16,666	-25%	$0.000000	50,002	10 Jan 2022	Common Stock	16,666	$1.78	Direct	F4
transaction	BLFS	Employee Stock Option	Options Exercise	$0	-16,666	-33%	$0.000000	33,336	12 Jan 2022	Common Stock	16,666	$1.78	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 1, 2020.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.67 to $31.53, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.17 to $32.19, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4	On February 07, 2017, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.